The Journal of Immunology, 1998, 161: 5039-5044.
Copyright © 1998 by The American Association of Immunologists
Thrombin Receptor Activation Inhibits Monocyte Spreading by Induction of ETB Receptor-Coupled Nitric Oxide Release1
Kamal D. Srivastava and
Harold I. Magazine2
Department of Biology, Queens College and Graduate School, City University of New York, Flushing, NY 11367
 |
Abstract
|
|---|
The effect of thrombin receptor activation on monocyte conformation
was evaluated using the human monocyte cell line, THP-1, and the
thrombin mimetic peptide, Trap-14. Treatment of THP-1 cells with
Trap-14 induced rapid rounding of ameboid cells adherent to
fibronectin-coated slides, whereas cell rounding was abrogated in the
presence of the nitric oxide synthase inhibitor,
NG-nitro-L-arginine or the endothelin B
receptor antagonist, BQ-788. Endothelin-1 (ET-1) levels in the culture
supernatant increased markedly within minutes of Trap-14 exposure with
a concomitant loss in cellular ET-1 immunoreactivity. Importantly, loss
of ET-1 immunoreactivity was blocked by pretreatment with the vesicle
translocation inhibitor, nocodazole. Trap-14 potently induced the
release of NO from THP-1 cells, whereas NO release was ablated by
preincubation with BQ-788. These data demonstrate that thrombin
receptor activation may inhibit cellular spreading as a result of
autocrine ET-1 release and subsequent endothelin B receptor-dependent
NO production, and suggest that initial exposure of inflammatory cells
to thrombin may limit cellular activation and
recruitment.
 |
Introduction
|
|---|
Inflammation
involves the recruitment of leukocytes to an injured area regulated by
cytokines and inflammatory mediators. Critical changes occur in the
morphology and adhesivity of leukocytes that allow them to leave the
circulation and collect at sites of injury. Aberrant modulation or
insufficient regulation of this process has been implicated in the
progression of inflammatory disease (1, 2). Thrombin is generated
rapidly following injury, and increasing evidence suggests an important
role for thrombin as an inflammatory mediator in addition to its
classical role in coagulation (3, 4). Thrombin increases endothelial
cell interactions with monocytes and neutrophils via up-regulation of
cellular adhesion molecules (5, 6) and has been shown to be chemotactic
for monocytes and neutrophils (7, 8). The capacity of thrombin to
modulate leukocyte properties such as conformation and motility
suggests that it may be of critical importance in the regulation of
inflammation. Monocyte interactions with thrombin and other members of
the coagulation cascade suggest connectivity between inflammatory and
coagulative processes (9). Studies have demonstrated up-regulated
cytokine expression and cytoskeletal changes in monocytes in response
to thrombin or thrombin mimetic peptides (10, 11). Few studies,
however, address the effect of thrombin on monocyte conformation.
Change in cell conformation is crucial to the process of monocyte
activation, and it is an accepted parameter for the designation of
monocyte activity. Activated monocytes characteristically spread and
extend pseudopodia to assume an ameboid conformation, whereas
inactivated cells lack such processes and appear round. In this study,
we have evaluated the effect of thrombin receptor activation on the
conformation of the human monocytic cell line, THP-1. We demonstrate
that thrombin receptor activation inhibits monocyte spreading on
fibronectin-coated slides and induces the rapid withdrawal of
pseudopodial processes, shifting the cellular conformation from ameboid
to round. Cell rounding is abrogated in the presence of nitric oxide
synthase (NOS)3 inhibitors,
suggesting a critical role for NO in the modulation of cell
conformation following thrombin receptor activation. These observations
are consistent with previous reports that demonstrate the ability of NO
to induce rounding of immune cells (12).
 |
Methods and Materials
|
|---|
Reagents
The thrombin receptor agonist peptide, Trap-14
(SFLLRNPNDKYEPF-amide), was synthesized on an Advanced ChemTech Model
90 peptide synthesizer exactly as described (13). Peptides were cleaved
with a mixture of 90% trifluoroacetic acid, 5% 1.2 ethanedithiol, 4%
water, and 1% thioanisol, and purified by C18 column chromatography
before use in assays. Endothelin receptor antagonists ETA
selective, BQ-123, and ETB selective, BQ-788, were
purchased from Peptides International (Louisville, KY). ET-1-specific
enzyme immunoassay (EIA) kit was obtained from Peninsula Laboratories
(Belmont, CA), whereas all other reagents were from Sigma (St. Louis,
MO). Trap-14 and ET receptor antagonists were dissolved in physiologic
salt solution (PSS) (130 mmol/L NaCl, 4.7 mmol/L KCl, 1.17
mmol/LMgSO4, 1.18 mmol/L KH2PO4,
14.9 mmol/L NaHCO3, 5.5 mmol/L dextrose, 0.03 mmol/L EDTA,
2.5 mmol/L CaCl2) or RPMI 1640 before use in assays.
Monoblastic cell line
The human monoblastic cell line, THP-1, was obtained from
American Type Culture Collection (Rockville, MD) and cultured in RPMI
1640 (Sigma) supplemented with 10% FBS (Life Technologies, Grand
Island, NY).
NO release
THP-1 cells were washed extensively with PSS just before use in
assays. Approximately 106 THP-1 cells were placed in 5 ml
of aerated (95% O2/5% CO2) PSS buffer and
maintained at 24°C, followed by evaluation of NO release using an
NO-specific amperometric probe, as described previously (14, 15). The
probe tip was immersed into the cell suspension, and following
establishment of baseline NO release (approximately 5 min), Trap-14 was
introduced in the medium and the concentration of NO gas in solution
was recorded by a computer-assisted data acquisition system at a
sampling rate of 1/s.
ET-1 release
Approximately 106 THP-1 cells were placed in 500
µl PSS and maintained at 24°C, followed by addition of vehicle (PSS
buffer) or Trap-14. ET-1 release observed following 5-min stimulation
with Trap-14 or vehicle was evaluated using an ET-1-specific EIA kit
(Peninsula Laboratories).
Immunodetection of ET-1 and NOS
THP-1 cells were washed and suspended in PSS and allowed to
adhere to Vectabond (Vector Laboratories, Burlingame, CA)-treated glass
slides. Cells were fixed with 3.7% formaldehyde for 10 min. After
extensive washing, the cells were permeabilized with 0.1% saponin for
15 min for detection of ET-1 or with 0.1% Triton-X for 5 min for
detection of constitutive NOS (cNOS). Cells were incubated with mouse
anti-human Ab to ET-1 (Peninsula Laboratories), or rabbit
anti-human cNOS (Signal Transduction Labs, Lexington, KY) for
1 h. After extensive washing with BSA-PSS, cells were incubated
with rhodamine-labeled goat anti-mouse or goat anti-rabbit
secondary Ab (Sigma) for 30 min. After washing, cells were postfixed
with 3.7% formaldehyde for 10 min. Following extensive washing, cells
were mounted with Fluoromount-G and coverslipped. Purified mouse or
rabbit IgG was used as negative control. Immunofluorescence was
evaluated by quantitative confocal microscopy (Meridian Ultima, Okemos,
MI) using a x40 objective and a pinhole of 1600 to evaluate total
cellular immunofluorescence for ET-1. For evaluation of cNOS
immunoreactivity, the cell was optically sectioned and cNOS
immunofluorescence was determined using a x100 objective and a pinhole
setting of 40 µM to provide an axial resolution of approximately 0.3
µM.
Evaluation of cellular conformation
THP-1 cells were washed extensively with RPMI 1640 and diluted
to a concentration of 106 cells/ml. Cell suspensions were
added to glass slides coated with 5 mg/ml fibronectin, whereupon they
were allowed to spread at 37°C for 1 h. After addition of
agonist, changes in cell conformation were evaluated at 15-min
intervals, as described previously (12, 16), using a x40 objective and
Nomarski optics (Nikon, TE-300). The degree of conformational change
was based on measurements of cellular area and perimeter using image
analysis software (Image Analytics, Hauppauge, NY). Changes in cellular
conformation that ranged from inactive-rounded to active-ameboid were
determined by measurement of cellular area and
perimeter and were mathematically expressed by use of the form
factor (FF) formula (4 x
A)/P2, in which A is the
area of the cell and P is the perimeter of that given cell (12). The
lower the FF value, the higher the cellular perimeter and the more
ameboid the cellular shape. Changes in cell conformation induced by
thrombin receptor activation were evaluated by addition of 100 µM
Trap-14 or vehicle alone (RPMI 1640) to cells once they became ameboid,
and changes in cell shape were followed for 1 h. For experiments
in the presence of ET receptor antagonists or NOS inhibitors, these
agents were added to the cell suspensions 15 min before addition of
Trap-14 and cell conformation was followed as described above.
Statistics
Data were evaluated using analysis of variance in which a
p value of <0.05 was considered to be statistically
significant. Multiple comparisons were adjusted using the Bonferroni
multirange test, with
set at 0.005.
 |
Results
|
|---|
Thrombin receptor activation triggers NO-dependent rounding of
THP-1 cells
To evaluate the effects of thrombin receptor activation on
cellular conformation, THP-1 cells adherent to fibronectin-coated
slides were treated with vehicle (RPMI 1640) or Trap-14, and cell shape
was visualized 1 h after exposure using computer-assisted
phase-contrast imaging. Untreated control THP-1 cells (Fig. 1
A) were ameboid, whereas
exposure to Trap-14 (Fig. 1
B) resulted in marked rounding of
the cells. Cellular rounding induced by thrombin was impaired by
pretreatment with the nonselective NOS inhibitor L-NNA
(Fig. 1
C). Form factor analysis was employed to evaluate the
extent of cell rounding. Form factor analysis describes the similarity
of a cell to a circle, with rounded cells having a value of greater
than 0.7 and ameboid cells having a value less than 0.5. The form
factor values of THP-1 cells treated with 100 µM Trap-14 were
increased significantly over a period of 1 h relative to that of
vehicle-treated control cells, indicating a potent rounding of THP-1
cells in response to Trap-14 (Fig. 1
D). Cell rounding was
inhibited significantly in the presence of L-NNA,
suggesting that Trap-14-induced rounding of THP-1 cells may be mediated
by NO.

View larger version (40K):
[in this window]
[in a new window]
|
FIGURE 1. Rounding of THP-1 cells in response to Trap-14. THP-1 cells were
allowed to adhere and spread on fibronectin-coated glass slides for
1 h, after which the cells were exposed to RPMI 1640
(A) or 100 µM Trap-14 (B and
C). Changes in cell conformation were evaluated over
1 h using Nomarski optics and computerized image analysis software
(Image Analytics). Observed at 1 h after stimulation, Trap-14
induced significant rounding of ameboid THP-1 cells (B)
when compared with control cells (A). This rounding was
blocked by pretreatment with the NOS inhibitor, L-NNA
(C). Numerical analysis of conformation over the course
of the experiment (D) indicates that cell rounding in
response to Trap-14 was rapid, with significant changes observed within
minutes (*, p < 0.05; **,
p < 0.001).
|
|
THP-1 cells release NO in response to Trap-14 stimulation
To evaluate the role of NO release in Trap-14-induced cell
rounding, NO release was measured using an amperometric probe.
Stimulation of THP-1 cells with Trap-14 resulted in a marked
increase in NO release, 43 ± 6 nM, that reached maximum within 5
min and returned to baseline levels within 10 min following
stimulation. Trap-14 activation of NOS was potently abrogated
by pretreatment with the NOS inhibitor L-NNA, 8 ± 3
nM (Fig. 2
, A and
B). The transient nature of NO release induced by Trap-14 is
consistent with that observed following activation of cNOS and is
similar to that observed following Trap-14 or thrombin stimulation of
vascular endothelium (14). We evaluated the presence of cNOS using a
selective mAb. Unstimulated THP-1 cells exhibited significant cNOS
immunofluorescence localized primarily to
the cell periphery (Fig. 3
A). The expression of cNOS
appeared to be clustered to areas of active cytoplasmic extension.
These data are consistent with previous localization studies of cNOS in
endothelial cells, in which cNOS was predominantly localized to
plasmalemmal caveolae (17). THP-1 cells stimulated with Trap-14 for 30
min resulted in a marked alteration in cNOS localization with
significant dispersion of cNOS throughout the cell (Fig. 3
B). The role of cNOS activation in Trap-14-induced NO
release is further supported by the observation that rounding of THP-1
cells by Trap-14 was inhibited by pretreatment with the nonselective
NOS inhibitor L-NNA, FF = 0.28 ± 0.06, whereas
pretreatment with the iNOS-selective inhibitor aminoguanidine, FF
= 0.74 ± 0.09, was without effect (Fig. 4
).

View larger version (21K):
[in this window]
[in a new window]
|
FIGURE 2. Real time evaluation of NO release from THP-1 cells. THP-1 cells were
stimulated with 100 µM Trap-14, and NO release was evaluated in real
time using an NO-specific amperometric probe (World Precision
Instruments, Sarasota, FL). A rapid increase in NO levels was detected
within 2 min of Trap-14 exposure to THP-1 cells, whereas
Trap-14-stimulated NO release in the presence of 10 µM
L-NNA was markedly attenuated (A). Analysis
of peak values of NO release demonstrated that Trap-14-induced NO
release was reduced significantly in the presence of L-NNA
(B) (*, p < 0.05, ANOVA).
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIGURE 3. Immunodetection of cNOS in THP-1 cells. THP-1 cells were fixed and
permeabilized, whereupon the cells were treated with a mAb specific for
cNOS and visualized with rhodamine-labeled secondary Ab. The
localization of cNOS expression was performed by confocal sectioning
using a x100 objective and 40 µM pinhole. Cellular cNOS expression
was evaluated by full reconstruction of all optical sections.
Unstimulated THP-1 cells exhibited intense cNOS expression
(A) that was localized primarily to regions at or in
close proximity to the plasma membrane. Following treatment with
Trap-14 for 30 min, that pattern of cNOS immunofluorescence was
markedly altered (B) with dispersion of cNOS throughout
the cell.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIGURE 4. Effect of NOS inhibitors on Trap-14-induced cell rounding.
Trap-14-induced cell rounding was evaluated in the presence of 1 µM
NOS inhibitor L-NNA or 10 µM iNOS-selective inhibitor,
aminoguanidine. Cells were allowed to adhere to fibronectin-coated
slides for 1 h, and cell conformation was evaluated before
addition of Trap-14 (open bars) and 1 h after Trap-14 treatment
(closed bars). Trap-14 induced cell rounding in the absence of NOS
inhibitors (None), while L-NNA significantly abrogated
Trap-14-induced cell rounding (*, p < 0.05,
ANOVA). Aminoguanidine had no effect, suggesting that the activity
was not mediated by activation of inducible NOS.
|
|
Trap-14-induced NO release is mediated by ET-1
Our laboratory has demonstrated previously that Trap-14-induced NO
release in rat aorta is mediated by autocrine ET-1 release with
subsequent activation of the ETB receptor (14). In this
study, we demonstrate the presence of ET-1 in THP-1 cells that is
released in response to Trap-14 exposure and a requirement of monocyte
ETB receptor activation for the induction of NO release.
ET-1 immunoreactivity was detected in THP-1 cells using fluorescent
confocal microscopy. Unstimulated THP-1 cells exhibited intense
ET-1-specific immunofluorescence that was reduced markedly following
5-min exposure to 100 µM Trap-14. The reduction in fluorescence
observed following Trap-14 exposure was abrogated by pretreatment of
THP-1 cells with the microtubular assembly inhibitor, nocodazole (Fig. 5
, AD). Consistent with the
mobilization of ET-1 following Trap-14 stimulation, release of ET-1 was
markedly increased, 177 ± 31 pM, following 5-min exposure to
Trap-14 relative to vehicle-treated control cells, 9 ± 12 pM
(Fig. 6
). These data are consistent with
our previous observations in which rapid release of ET-1 was observed
following thrombin or Trap-14 stimulation of rat aorta (13, 14), and
suggest that thrombin receptor activation may trigger the mobilization
of ET-1 from vesicular storage sites.

View larger version (32K):
[in this window]
[in a new window]
|
FIGURE 5. ET-1 mobilization. For immunodetection of ET-1, THP-1 cells were
formaldehyde fixed and saponin permeabilized, whereupon the cells were
evaluated for the presence of immunoreactive ET-1 using a mAb specific
for ET-1 (Bioaffinity Labs) and rhodamine-labeled secondary Ab.
Fluorescent images were obtained by confocal microscopy, and
fluorescence values (in pixels) were obtained by computer analysis
(Meridian Instruments, Lansing, MI). Intense ET-1 immunofluorescence
was detected in untreated THP-1 cells (A), whereas a
marked reduction in fluorescence was observed in THP-1 cells exposed to
Trap-14 (B). ET-1 immunofluorescence was not reduced by
Trap-14 in the presence of 1 nM nocodazole (C). Analysis
of fluorescence values for the above experiment (D)
indicates a significant loss in ET-1 immunoreactivity in response to
Trap-14 (*, p < 0.05, ANOVA), suggesting the
release of ET-1. The loss was abrogated by pretreatment with
nocodazole, suggesting that rapid release of ET-1 is dependent upon
microtubular assembly.
|
|

View larger version (11K):
[in this window]
[in a new window]
|
FIGURE 6. ET-1 release. THP-1 cells were treated with 100 µM Trap-14 for 5 min,
whereupon the culture supernatant was assayed for the presence of ET-1
by ET-1-specific immunoassay (Peninsula Laboratories). Treatment of
THP-1 cells with Trap-14, but not vehicle alone, resulted in a
significant increase in ET-1 levels detected in the culture supernatant
(*, p < 0.05, ANOVA).
|
|
To evaluate the role of ET receptor activation in thrombin-induced NO
release from monocytes, THP-1 cells were pretreated with an antagonist
specific for the ETA (BQ-123) or ETB (BQ-788)
receptor subtype, and NO release following thrombin receptor activation
was evaluated. Trap-14-induced release of NO was abrogated by
pretreatment with the ETB, 9 ± 4 nM, but not the
ETA receptor antagonist, 49 ± 5 nM (Fig. 7
). These data coupled to our previous
demonstration of thrombin-induced NO release in vascular endothelium by
an ETB receptor-dependent mechanism suggest that thrombin
receptor activation-induced NO release from monocytes may be indirect
and requires ET-1 release and subsequent ETB receptor
activation.

View larger version (14K):
[in this window]
[in a new window]
|
FIGURE 7. Contribution of ET-1 to Trap-14-induced NO release. NO release
from THP-1 cells induced by 100 µM Trap-14 was evaluated in the
presence and absence of 0.1 µM ET receptor antagonists,
ETA-selective BQ-123 or ETB-selective BQ-788,
and peak values for NO release were determined. Maximal production of
NO induced by Trap-14 was markedly attenuated in the presence of
BQ-788, but not BQ-123 (*, p < 0.05,
ANOVA).
|
|
Trap-14-induced conformational changes require ETB
receptor activation
The contribution of ET-1 activity to cell rounding was
evaluated using phase-contrast microscopy and image analysis software,
as described above. Trap-14-induced cell rounding (Fig. 8
A) was inhibited by
pretreatment with the ETB-selective antagonist BQ-788 (Fig. 8
B), but not by the ETA-selective antagonist
BQ-123 (Fig. 8
C). Numerical analysis of data collected over
the course of the experiment (Fig. 8
D) demonstrates the
significant attenuation of Trap-14-induced cell rounding by the
ETB-selective antagonist BQ-788, suggesting a requirement
for ETB receptor activation. Taken together, these data
demonstrated that acute exposure of THP-1 cells to the thrombin mimetic
peptide Trap-14 induces cell rounding that is mediated by cNOS-coupled
release of NO, and this activity requires ET-1 release and subsequent
activation of the ETB receptor.
 |
Discussion
|
|---|
Recent reports have suggested an important role for thrombin in
inflammation in addition to its established function as a procoagulant.
While its ability to augment endothelial adhesivity toward leukocytes
attributed to up-regulation of endothelial adhesion molecules is well
known, leukocyte responses to thrombin are as yet poorly defined.
Previous reports have demonstrated that thrombin is chemotactic for
monocytes (8) and that it induces up-regulated release of
monocyte-chemotactic protein-1 and LPS-induced cytokines (18). Few
studies have evaluated the response of monocytes to thrombin in terms
of cellular conformation, a classical indicator of monocyte activation.
Activated monocytes characteristically spread and extend pseudopodia to
assume an ameboid conformation (12). This report studies the effect of
thrombin receptor activation on the conformation of the monocytic cell
line THP-1 and demonstrates that acute exposure of adherent THP-1 cells
to the thrombin mimetic peptide Trap-14 induces rapid cell rounding.
Cell rounding is inhibited by pretreatment with the NOS inhibitor
L-NNA, suggesting that the activity is mediated by NO.
Consistent with a critical role for NO in Trap-14-induced cell
rounding, we observed the release of nanomolar quantities of NO from
THP-1 cells in response to Trap-14. The ability of NO to affect cell
conformation has only recently been appreciated, and recent evidence
suggests that this activity is mediated by alteration of cytoskeletal
actin (19, 20). The rapid and transient profile of NO release and
inability of the iNOS-selective inhibitor aminoguanidine to inhibit
subsequent cell rounding implicate the involvement of the constitutive
pathway of NO synthesis in Trap-14-induced cell rounding. While cNOS
activity in monocytic cells has been an issue of some debate, the
presence of cNOS in THP-1 cells has been demonstrated recently by
Reiling et al. (21), and cNOS activity in monocytes has been
demonstrated by others (22). Immunofluorescence studies described in
this study demonstrate expression of cNOS in unstimulated THP-1 cells
with predominant localization at or in close proximity to the plasma
membrane. Following stimulation with Trap-14, a rapid dispersion of
cNOS was observed, suggesting cNOS activation in THP-1 cells treated
with Trap-14. Optical sectioning of THP-1 cells by confocal microscopy
revealed significant cNOS immunofluorescence 2.4 µM below the plasma
membrane in Trap-14-treated, but not control THP-1 cells (not shown).
These data are consistent with the demonstration by others of
predominant localization of cNOS in caveolae of endothelial cells
with rapid release into the cytosol following activation (17, 23).
NO release from Trap-14-stimulated THP-1 cells and subsequent cell
rounding are blocked by pretreatment with an ETB receptor
antagonist and are consistent with the mechanism for Trap-14 induction
of NO previously described in rat aortic rings (13). In this study, we
demonstrate that THP-1 cells release ET-1 within minutes of Trap-14
stimulation. Although up-regulated ET-1 release from monocytes 24
h after stimulation with thrombin has been described previously (24),
the rapid nature of ET-1 release demonstrated in this work is novel.
Mobilization of ET-1 was observed within minutes of thrombin receptor
activation, and was inhibited by nocodazole, an inhibitor of
microtubular assembly. Taken together, these observations suggest that
a pool of ET-1 is present in vesicular storage sites in monocytes.
While the presence of ET-1 vesicles in vascular endothelium has been
suggested by others (25, 26), this is the first demonstration of ET-1
storage in monocytes and it provides evidence to suggest a role for
autocrine ET-1 release in the modulation of monocyte reactivity.
Rounding of THP-1 cells in response to Trap-14 suggests that activation
of the thrombin receptor may paradoxically inhibit monocytic spreading.
This observation is seemingly at odds with the prevailing reputation of
thrombin as a proinflammatory mediator. It must be noted, however, that
studies investigating the role of thrombin as an inflammatory mediator
primarily evaluate the effect of thrombin on the endothelium. While a
few reports have addressed cytokine release and chemotaxis by
leukocytes in response to thrombin, little is known about
thrombin-induced changes in leukocyte reactivity and the contribution
of such changes to leukocyte recruitment. From the time of initial
mobilization of leukocytes from the circulation, until their ultimate
extravasation to the primary site of injury, extensive interaction
exists between leukocytes and endothelium to ensure strict spatial and
temporal regulation of inflammation. Current models proposed to explain
the process of leukocyte recruitment have suggested the necessity of
negative regulation of leukocyte reactivity (27). NO has been
implicated as an agent that inhibits leukocyte activity (28, 29), and
excessive accumulation of leukocytes after inhibition of NO synthesis
is well known (30, 31). We propose that thrombin receptor activation
triggers the rapid release of ET-1 from vesicles, and subsequent
binding of ET-1 to ETB receptors results in rapid and
transient cNOS-coupled NO production (Fig. 9
). Functional coupling of
ETB receptor activation to NO release has been shown
previously (13, 14), and this pathway is further supported by
independent demonstration of cNOS and ET receptor localization in
caveolae by others (17, 32). Cytoskeletal actin may be disrupted
following ADP-ribosylation induced by NO, resulting in destabilization
of pseudopodial extensions and cellular rounding. The negative
regulation of leukocyte reactivity by thrombin would be relieved by
down-regulation of ETB receptor signaling or cNOS activity.
Such modulation may be instrumental in restricting inappropriate
leukocyte reactivity, thereby ensuring strict regulation of
inflammatory response progression.

View larger version (16K):
[in this window]
[in a new window]
|
FIGURE 9. Inhibition of monocyte spreading by thrombin. We propose a model in
which thrombin receptor activation triggers the rapid exocytosis of
ET-1 from preformed vesicles with subsequent binding of ET-1 to
monocyte ETB receptors. An influx of extracellular
Ca2+ triggered by ETB receptor activation may
activate cNOS, resulting in the rapid and transient production of NO.
The concentration of ETB receptors and cNOS in caveolae may
potentiate and localize the effects of thrombin-induced NO release.
ADP-ribosylation of actin mediated by NO may result in depolymerization
of actin in pseudopodial extensions, resulting in inhibition of cell
spreading and alteration of cell conformation from ameboid to
round.
|
|
 |
Acknowledgments
|
|---|
We thank Jeanette Schaeffer and Queens College Image Core Facility
for technical assistance. Graphic output was supported by a generous
gift from Queens College Biology Department, Alumni Fund.
 |
Footnotes
|
|---|
1 This work was supported by a grant from the American Heart Association, 9750211N, and the City University of New York Internal Awards Program, PSC-City University of New York. 
2 Address correspondence and reprint requests to Dr. Harold I. Magazine, Department of Biology, Queens College, 65-30 Kissena Blvd., Flushing, NY 11367. E-mail address: 
3 Abbreviations used in this paper: NO, nitric oxide; cNOS, constitutive nitric oxide synthase; EIA, enzyme-linked immunoassay; ET, endothelin; FF, form factor; iNOS, inducible NOS; L-NNA, NG-nitro-L-arginine; NOS, nitric oxide synthase; PSS, physiologic salt solution. 
Received for publication March 9, 1998.
Accepted for publication July 1, 1998.
 |
References
|
|---|
-
Figdor, C. G., Y. Vankooyk. 1992. Regulation of cell adhesion. J. M. Harlan, and D. Y. Liu, eds. Adhesion: Its Role in Inflammatory Disease 151. WH Freeman and Co., New York.
-
Mulligan, M. S., M. J. Polley, R. J. Bayer, M. F. Nunn, J. C. Paulson, P. A. Ward. 1992. Neutrophil-dependent acute lung injury. J. Clin. Invest. 90:1600.
-
Moulin, F., J. M. Pearson, A. E. Schultze, M. A. Scott, K. A. Schwartz, J. M. Davis, P. E. Ganey, R. A. Roth. 1996. Thrombin is a distal mediator of lipopolysaccharide-induced liver injury in the rat. J. Surg. Res. 65:149.[Medline]
-
Walters, T. K., D. A. Gorog, R. F. Wood. 1994. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. J. Vasc. Res. 31:173.[Medline]
-
Shankar, R., C. A. de la Motte, P. E. DiCorleto. 1992. Thrombin stimulates PDGF production and monocyte adhesion through distinct intracellular pathways in human endothelial cells. Am. J. Physiol. 262:C199.[Abstract/Free Full Text]
-
Toothill, V. J., J. A. Van Mourik, H. K. Niewenhuis, M. J. Metzelaar, J. D. Pearson. 1990. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. J. Immunol. 145:283.[Abstract]
-
Bizios, R., L. Lai, J. W. Fenton, A. B. Malik. 1986. Thrombin-induced chemotaxis and aggregation of neutrophils. J. Cell. Physiol. 128:485.[Medline]
-
Crago, A. M., H. F. Wu, M. Hoffman, F. C. Church. 1995. Monocyte chemoattractant activity of Ser195
Ala active site mutant recombinant
-thrombin. Exp. Cell Res. 219:650.[Medline]
-
Worfolk, L. A., R. A. Robinson, P. B. Tracy. 1992. Factor Xa interacts with two sites on monocytes with different functional activities. Blood 80:1989.[Abstract/Free Full Text]
-
Ritchie, H., A. Jamieson, N. A. Booth. 1995. Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. Blood 86:3428.[Abstract/Free Full Text]
-
Joseph, S., J. MacDermot. 1992. Thrombin promotes actin polymerization in U937 human monocyte-macrophage cells: analysis of the signalling mechanisms mediating actin polymerization. Biochem. J. 286:945.
-
Magazine, H. I., Y. Liu, T. V. Bilfinger, G. L. Fricchione, G. B. Stefano. 1996. Morphine-induced conformational change in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. J. Immunol. 156:4845.[Abstract]
-
Magazine, H. I., O. Butt, H. R. Yaghoutiel. 1996. Endothelin and nitric oxide release modulate aortic contraction to selected thrombin agonists. Am. J. Physiol. 270:C1815.[Abstract/Free Full Text]
-
Magazine, H. I., K. Srivastava. 1996. Thrombin-induced vascular reactivity is modulated by ETB receptor coupled nitric oxide release in rat aorta. Am. J. Physiol. 271:C923.[Abstract/Free Full Text]
-
Magazine, H. I. 1995. Detection of endothelial cell
derived nitric oxide: current trends and future directions. In
Advances in Neuroimmunology, Vol. 5. pp. 47990.
-
King, J. M., K. D. Srivastava, G. B. Stefano, T. V. Bilfinger, W. F. Bahou, H. I. Magazine. 1997. Human monocyte adhesion is modulated by endothelin B receptor coupled nitric oxide release. J. Immunol. 158:880.[Abstract]
-
Garcia-Cardena, G., P. Oh, J. Liu, J. E. Schnitzer, W. C. Sessa. 1996. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl. Acad. Sci. USA 93:6448.[Abstract/Free Full Text]
-
Colotta, F., F. L. Sciacca, M. Sironi, W. Luini, M. J. Rabiet, A. Mantovani. 1994. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am. J. Pathol. 144:975.[Abstract]
-
Clancy, R. M., J. Leszczynska-Piziak, S. B. Abramson. 1993. Nitric oxide stimulates the ADP-ribosylation of actin in human neutrophils. Biochem. Biophys. Res. Commun. 191:847.[Medline]
-
Jun, C. D., M. K. Han, U. H. Kim, H. T. Chung. 1996. Nitric oxide induces ADP-ribosylation of actin in murine macrophages: association with the inhibition of pseudopodia formation, phagocytic activity, and adherence on a laminin substratum. Cell. Immunol. 174:25.[Medline]
-
Reiling, N., A. J. Ulmer, M. Duchrow, M. Ernst, H. D. Flad, S. Hauschildt. 1994. Nitric oxide synthase: mRNA expression of different isoforms in human monocytes/macrophages. Eur. J. Immumol. 24:1941.[Medline]
-
Aubry, J. P., N. Dugas, S. Lecoanet-Henchoz, F. Ouaaz, H. Zhao, J. F. Delfraissy, P. Graber, J. P. Kolb, B. Dugas, J. Y. Bonnefoy. 1997. The 25-kDa soluble CD23 activates type III constitutive nitric oxide synthase activity via CD11b and CD11c expressed by human monocytes. J. Immunol. 159:614.[Abstract]
-
Michel, T., G. K. Li, L. Busconi. 1993. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 90:6252.[Abstract/Free Full Text]
-
Ehrenreich, H., P. Rieckmann, F. Sinowatz, K. A. Weih, L. O. Arthur, F. D. Goebel, P. R. Burd, J. E. Coligan, K. A. Clouse. 1993. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. Immunology 150:4601.
-
Harrison, V. J., K. Barnes, A. J. Turner, E. Wood, R. Corder, J. R. Vane. 1995. Identification of endothelin 1 and big endothelin 1 in secretory vesicles isolated from bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA 92:6344.[Abstract/Free Full Text]
-
Tasaka, K., K. Kitazumi. 1994. The control of endothelin-1 secretion. Gen. Pharmacol. 25:1059.[Medline]
-
Argenbright, W. L.. 1995. Inflammatory mediators, cytokines, and leukocyte adhesion in post capillary venules. D. N. Granger, and G. W. Schmidt-Schoenbien, eds. Physiology and Pathophysiology of Leukocyte Adhesion 171. Oxford University Press, New York.
-
Kubes, P., M. Suzuki, D. N. Granger. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 88:4651.[Abstract/Free Full Text]
-
De Caterina, R., P. Libby, H. B. Peng, V. J. Thannickal, T. B. Rajavashisth, Jr M. A. Gimbrone, W. S. Shin, J. K. Liao. 1995. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96:60.
-
Akimitsu, T., D. C. Gute, R. J. Korthuis. 1995. Leukocyte adhesion induced by inhibition of nitric oxide production in skeletal muscle. J. Appl. Physiol. 78:1725.[Abstract/Free Full Text]
-
Kubes, P., S. Kanwar, X. F. Niu, J. P. Gaboury. 1993. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J. 7:1293.[Abstract]
-
Chun, M., U. K. Liyanage, M. P. Lisanti, H. F. Lodish. 1994. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc. Natl. Acad. Sci. USA 91:11728.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
H. I. Magazine, J. Chang, Y. Goumon, and G. B. Stefano
Rebound from Nitric Oxide Inhibition Triggers Enhanced Monocyte Activation and Chemotaxis
J. Immunol.,
July 1, 2000;
165(1):
102 - 107.
[Abstract]
[Full Text]
[PDF]
|
 |
|